drug

erdafitinib

1 story · latest Nov 6, 2026

Follow erdafitinib. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.

Follow free for 14 daysNo card.

Status: FDA approved Apr 2019 · NDA212018
Brand: Balversa

Relationships

Developed by Johnson & Johnson

Timeline

FDA approved erdafitinib for FGFR3-altered metastatic urothelial carcinoma in 2024

Nov 6Regulatory decisionerdafitinib Johnson & Johnson

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.